USA flag logo/image

An Official Website of the United States Government

Neurogenic Compounds for Treating Diabetic Complications

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
71577
Program Year/Program:
2004 / SBIR
Agency Tracking Number:
DK069733
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
BIOMEDICAL RESEARCH MODELS, INC.
67 MILLBROOK, ST, STE 422 WORCESTER, MA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2004
Title: Neurogenic Compounds for Treating Diabetic Complications
Agency: HHS
Contract: 1R43DK069733-01
Award Amount: $1,000,000.00
 

Abstract:

DESCRIPTION (provided by applicant): Neuronal dysfunction is the leading complication associated with diabetes. Diabetic patients experience both cognitive impairment and a collection of syndromes termed "diabetic neuropathies". Although many of the pathways involved in initiating hyperglycemic-induced neuronal degeneration have been identified, promising therapies directed at preventing and alleviating symptoms are still lacking. With funding from the DOD, we have identified several small molecules which both enhance neurogenesis and protect neurons from apoptosis. We propose to develop these molecules as new compounds to treat neuronal dysfunction in type 1 diabetes. In Phase 1, we will re-screen our leading compounds to determine which compounds protect neurons in diabetes-specific in vitro assays. We will then determine whether prophylactic administration of these compounds has an effect on cognitive impairment and early symptoms of diabetic polyneuropathy in a rat model of spontaneous type 1 diabetes. In addition, we will perform dose response, acute toxicity and pharmacokinetic studies. Based on these results, we will choose one lead compound for further studies. In Phase 2 we will determine whether the lead compound also acts therapeutically when given within a certain time period post onset of diabetes. We will expand toxicity studies and we will test the molecule in a variety of diabetic animal models. The end result of these studies will be the identification of one lead compound to be developed as an IND/therapy in the treatment of diabetic polyneuropathy and/or diabetic encephalopathy.

Principal Investigator:

Rebecca S. Tirabassi
5084597544
RTIRABASSI@BIOMERE.COM

Business Contact:


5084597544
Small Business Information at Submission:

BIOMEDICAL RESEARCH MODELS, INC.
BIOMEDICAL RESEARCH MODELS, INC. 67 MILLBROOK, ST, STE 422 WORCESTER, MA 01606

EIN/Tax ID: 043338250
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No